🇺🇸 FDA
Patent

US 7863262

Nitroxyl progenitors in the treatment of heart failure

granted A61KA61K31/13A61K31/16

Quick answer

US patent 7863262 (Nitroxyl progenitors in the treatment of heart failure) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Dec 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jan 04 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/13, A61K31/16, A61K31/655, A61K33/00